Natera

BOSTON – October 29, 2026 -- TransCode Therapeutics (Nasdaq: RNAZ) has opened a formal strategic process that could end in a sale or licensing of its oncology assets, a partnership or a business combination, with lead candidate TTX-MC138 now in Phase 2a development.

Tungsten Advisors to run the process as exclusive financial advisor

The Board of Directors initiated the review to maximize the value of the company and its oncology portfolio. Options include licensing or selling individual assets, development and commercialization partnerships, portfolio transactions and business combinations. TransCode has engaged Tungsten Advisors as exclusive strategic financial advisor.

CEO and Chairman Philippe P. Calais said the process is meant to support continued development of TTX-MC138 while seeking to maximize value for stockholders.

SALT LAKE CITY – October 28, 2026 -- Thorne converted 80% of its paper batch records to electronic batch records (EBR) in 2026 using MasterControl Manufacturing Excellence (Mx), earning the Manufacturing Excellence Award at MasterControl's 2026 Masters Summit. The October event named four winners of the Masters of Excellence Awards, which recognize MasterControl customers in quality management, manufacturing, asset excellence and innovation.

Thorne targets full electronic batch record rollout by year-end

Thorne aims to complete its EBR implementation by the end of 2026, with MasterControl Logbooks planned next. After five years on MasterControl, the company reports measurable gains in right-first-time rates, record review and release times, and quality performance.